阿斯利康与加科思药业就泛KRAS抑制剂JAB-23E73达成全球独家许可协议

Core Viewpoint - AstraZeneca and Gossamer Bio have entered into a global exclusive licensing agreement for the KRAS inhibitor JAB-23E73, with AstraZeneca obtaining exclusive rights for development and commercialization outside of China, while Gossamer will collaborate with AstraZeneca for the product in the Chinese market [1] Group 1 - AstraZeneca will pay Gossamer Bio an upfront payment of $100 million [1] - Gossamer Bio is eligible for up to $1.915 billion in additional milestone payments related to development and commercialization [1] - AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China [1]